Daily Roundup

ALC.ASX CSL.ASX CU6.ASX SWM.ASX RKN.ASX

Alcidion Secures Major Contract in Wales

Alcidion Group Limited has scored a significant win, securing a contract with Hywel Dda University Health Board in Wales. The deal will see Alcidion provide its Miya Precision Platform, including patient flow management, observations and assessments, and clinical communications tools. The contract is valued at a hefty $5.5 million over 5 years, with an option to extend it to 7 years, potentially increasing the total value to $7.7 million. This marks Alcidion's first contract with a Welsh health board, and it comes at an exciting time as the country looks to boost its digital healthcare capabilities.

CSL Delivers Solid Half-Year Results

Biotech giant CSL has reported a healthy set of financials for the first half of fiscal year 2025. Revenue climbed 5% to $8.48 billion, while net profit after tax rose 6% to $2.01 billion. The company's core Immunoglobulin and Haemophilia product segments were the standout performers. Looking ahead, CSL is forecasting revenue growth of 5-7% and net profit growth of 10-13% for the full fiscal year.

Clarity Expands Cancer Pipeline with Trastuzumab Theranostic

Clarity Pharmaceuticals is bolstering its Targeted Copper Theranostic (TCT) portfolio with a new asset - 64/67Cu-SAR-trastuzumab. Preclinical data shows this novel theranostic product has potential for treating HER2-positive breast cancer, an area of significant unmet need. Clarity has also secured a supply agreement for the required trastuzumab biosimilar, putting it in a strong position to advance this program. This addition complements Clarity's existing focus on prostate cancer, neuroblastoma and neuroendocrine tumours.

Seven West Media Weathers Advertising Headwinds

It's been a challenging half-year for Seven West Media, with the company reporting a 6.2% decline in revenue and other income to $727.3 million. EBIT fell 32.8% to $71 million, while profit after tax excluding significant items dropped 40.2% to $37.4 million. The company cited softness in the TV advertising market and the impact of specific one-off events as the key factors behind the weaker performance. However, Seven's content strategy and the growth of its 7plus digital platform provide reasons for optimism.

Reckon Sees Modest Growth but Profit Decline

Accounting software provider Reckon Ltd has posted its preliminary full-year results for 2024, revealing a mixed bag. Revenue increased 1.3% to $54.1 million, and EBITDA grew 2.5% to $20.2 million. However, net profit declined 25.7% to $3.6 million, partly due to the absence of a research and development grant benefit that boosted the prior year's bottom line. The company's net tangible assets position also remained in negative territory.